New drug tested for Tough-to-Treat stomach and intestinal cancers
NCT ID NCT05411133
Summary
This first-in-human study tested a new drug called Cabotamig in 33 adults with advanced gastrointestinal cancers that had stopped responding to standard treatments. The main goals were to check the drug's safety, see how the body processes it, and look for early signs that it might affect tumors. The trial specifically enrolled patients whose cancer cells carried a certain marker called CDH17.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Queen Mary Hospital
Hong Kong, Hong Kong
-
Southern Oncology Clinical Research Unit
Adelaide, Australia
-
St George Private Hospital
Sydney, Australia
Conditions
Explore the condition pages connected to this study.